JP2008501716A5 - - Google Patents

Download PDF

Info

Publication number
JP2008501716A5
JP2008501716A5 JP2007515646A JP2007515646A JP2008501716A5 JP 2008501716 A5 JP2008501716 A5 JP 2008501716A5 JP 2007515646 A JP2007515646 A JP 2007515646A JP 2007515646 A JP2007515646 A JP 2007515646A JP 2008501716 A5 JP2008501716 A5 JP 2008501716A5
Authority
JP
Japan
Prior art keywords
medicament
syndrome
disease
autoinflammatory
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007515646A
Other languages
English (en)
Japanese (ja)
Other versions
JP5022216B2 (ja
JP2008501716A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/019674 external-priority patent/WO2005117945A1/en
Publication of JP2008501716A publication Critical patent/JP2008501716A/ja
Publication of JP2008501716A5 publication Critical patent/JP2008501716A5/ja
Application granted granted Critical
Publication of JP5022216B2 publication Critical patent/JP5022216B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007515646A 2004-06-04 2005-06-03 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法 Expired - Fee Related JP5022216B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57702304P 2004-06-04 2004-06-04
US60/577,023 2004-06-04
PCT/US2005/019674 WO2005117945A1 (en) 2004-06-04 2005-06-03 Methods of using il-1 antagonists to treat autoinflammatory disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012012800A Division JP2012111768A (ja) 2004-06-04 2012-01-25 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法

Publications (3)

Publication Number Publication Date
JP2008501716A JP2008501716A (ja) 2008-01-24
JP2008501716A5 true JP2008501716A5 (enExample) 2008-04-24
JP5022216B2 JP5022216B2 (ja) 2012-09-12

Family

ID=34972252

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007515646A Expired - Fee Related JP5022216B2 (ja) 2004-06-04 2005-06-03 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法
JP2012012800A Pending JP2012111768A (ja) 2004-06-04 2012-01-25 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012012800A Pending JP2012111768A (ja) 2004-06-04 2012-01-25 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法

Country Status (9)

Country Link
US (4) US7459426B2 (enExample)
EP (1) EP1750746A1 (enExample)
JP (2) JP5022216B2 (enExample)
CN (1) CN1964737B (enExample)
AU (1) AU2005249570B2 (enExample)
CA (1) CA2568352C (enExample)
IL (1) IL179512A0 (enExample)
MX (2) MXPA06014126A (enExample)
WO (1) WO2005117945A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2784090A1 (en) 2004-02-26 2014-10-01 Baylor Research Institute Compositions for the treatment of systemic onset juvenile idiopathic arthritis
CA2567080A1 (en) * 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases
WO2006076673A2 (en) * 2005-01-14 2006-07-20 Regeneron Pharmaceuticals, Inc. Use of il-i antagonists to treat polymyalgia rheumatica and giant cell arteritis
PL2848258T3 (pl) * 2005-10-26 2018-06-29 Novartis Ag Leczenie rodzinnej gorączki śródziemnomorskiej przeciwciałami przeciwko IL-1beta
CN101378764A (zh) * 2005-12-09 2009-03-04 贝勒研究院 通过血液白细胞微阵列分析对系统性红斑狼疮的诊断、预后和疾病发展的监测
US7632490B2 (en) 2006-10-20 2009-12-15 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
AU2007309470B2 (en) * 2006-10-20 2013-05-23 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout and pseudogout
WO2008093756A1 (ja) * 2007-01-30 2008-08-07 Niigata University 生物学的製剤
WO2008112772A2 (en) * 2007-03-14 2008-09-18 Baylor Research Institute Gene expression in peripheral blood mononuclear cells from children with diabetes
KR101591533B1 (ko) * 2007-05-29 2016-02-03 노파르티스 아게 항-ｉｌ-1-베타 치료법에 대한 신규 적응증
CN102869775A (zh) 2009-09-30 2013-01-09 哈佛大学校长及研究员协会 通过调节自噬抑制基因产物调节自噬的方法
PT2582391T (pt) 2010-06-18 2019-01-11 Xbiotech Inc Tratamento da artrite
CN107337735B (zh) 2010-07-29 2021-06-22 巴扎德制药公司 嵌合il-1受体i型激动剂和拮抗剂
CU23923B1 (es) * 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
HRP20191494T1 (hr) * 2012-03-31 2019-11-29 R Pharm Int Llc Pripravak derivat osteoprotegerina i njegova uporaba
CN103509100B (zh) * 2012-06-15 2017-10-27 上海百迈博制药有限公司 一种白细胞介素‑1受体拮抗剂突变体
WO2014035361A1 (en) * 2012-08-26 2014-03-06 R-PHARM, CJSC (Closed Joint Stock Company) IL-1β INHIBITOR COMPOSITION AND USE THEREOF
PL2968468T3 (pl) 2013-03-13 2021-12-20 Buzzard Pharmaceuticals AB Preparaty chimerycznej cytokiny do dostarczania do oka
JP2016520615A (ja) * 2013-05-31 2016-07-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法
CN105658672A (zh) * 2013-08-22 2016-06-08 阿塞勒隆制药公司 TGF-β受体II型变体及其用途
WO2015147789A1 (en) * 2014-03-24 2015-10-01 R-Pharm Overseas, Inc. Human il 1-r1 derived inhibitor of il-1b
JP6565099B2 (ja) * 2015-09-18 2019-08-28 国立大学法人 長崎大学 家族性地中海熱のバイオマーカー
US10183060B2 (en) * 2015-10-01 2019-01-22 Heat Biologics, Inc. Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins
CA3016277A1 (en) * 2016-03-09 2017-09-14 The University Of Adelaide Methods for reducing perinatal morbidity and/or mortality
KR20190117579A (ko) * 2017-02-16 2019-10-16 엑스바이오테크, 인크. 화농성 한선염의 치료
AU2018249816B2 (en) * 2017-04-03 2025-04-17 Wisconsin Alumni Research Foundation Mineral coated microparticles for sustained delivery of biologically active molecules
JP2022524178A (ja) * 2019-01-07 2022-04-28 セルリス パルティシパソエス リミターダ タンデム受容体ｃａｒにおける二重特異性と腫瘍マイクロ環境を変調する方法
EP4054564A1 (en) * 2019-11-07 2022-09-14 Inflazome Limited Treatment of autoinflammatory disorders
JP7072260B2 (ja) * 2019-12-27 2022-05-20 国立大学法人愛媛大学 マックル・ウェルズ症候群の治療用医薬組成物
WO2021184128A1 (en) * 2020-03-20 2021-09-23 Institut De Cardiologie De Montreal Methods of treating a coronavirus infection using colchicine
TW202210068A (zh) * 2020-06-05 2022-03-16 美商雅力思提雅治療公司 用於治療家族性地中海型發熱病的cxcr-2抑制劑

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
EP2241328A1 (en) * 2000-05-12 2010-10-20 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
ME00204B (me) 2002-09-06 2011-02-10 Medarex Llc Terapijsko, humano, monoklonsko anti-il-1r1antitijelo
US20050129685A1 (en) * 2003-09-18 2005-06-16 Jingtai Cao Use of IL-1 blockers to prevent corneal inflammation and neovascularization

Similar Documents

Publication Publication Date Title
JP2008501716A5 (enExample)
Kopf et al. Averting inflammation by targeting the cytokine environment
CA2568352A1 (en) Methods of using il-1 antagonists to treat autoinflammatory disease
Malcova et al. IL-1 inhibitors in the treatment of monogenic periodic fever syndromes: from the past to the future perspectives
Assier et al. Interleukin-6: from identification of the cytokine to development of targeted treatments
Gurczynski et al. IL-17 in the lung: the good, the bad, and the ugly
Nishimoto Interleukin‐6 as a therapeutic target in candidate inflammatory diseases
ES2660036T3 (es) Moléculas de anticuerpo humanizadas específicas para IL-31
Izuhara et al. IL-4 and IL-13: their pathological roles in allergic diseases and their potential in developing new therapies
JP2009539349A5 (enExample)
Geyer et al. Actual status of antiinterleukin-1 therapies in rheumatic diseases
JP2011507891A5 (enExample)
CN1322897C (zh) Il－18抑制剂的应用
JP2017079785A5 (enExample)
Tanasescu et al. Advances in the treatment of relapsing-remitting multiple sclerosis
HRP20150790T1 (hr) Režimi imunoterapije koji ovise o statusu apoe
JP2009510025A5 (enExample)
JP2006506465A5 (enExample)
ME00519B (me) Antitijela visokog afiniteta prema humanom il-6 receptoru
NZ597915A (en) Combination therapy for treatment of immune disorders
US10456456B2 (en) Anti-IL-6 vaccine composition
McDermott Rilonacept in the treatment of chronic inflammatory disorders
Finckh et al. At the horizon of innovative therapy in rheumatology: new biologic agents
Çakan et al. Canakinumab in colchicine resistant familial Mediterranean fever and other pediatric rheumatic diseases
Scharl et al. new anti-cytokines for IBD: what is in the pipeline?